Clinical Trial Update: Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding Herceptin to a carboplatin-paclitaxel regimen for ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED